Measurement of Matrix Metalloproteinases (Mmps) and Tissue Inhibitors of Metalloproteinases (Timp) in Blood and Urine: Potential Clinical Applications

Advances in Clinical Chemistry

Volumn 38, Issue , 2004, Pages 37-85

  Zucker, Stanley ^a   Doshi, Kaushik ^a   Cao, Jian ^b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MATRIX METALLOPROTEINASE;

BLOOD; CLASSIFICATION; CLINICAL CHEMISTRY; GENERAL ASPECTS OF DISEASE; HUMAN; REVIEW; URINE;

CLINICAL CHEMISTRY TESTS; DISEASE; HUMANS; MATRIX METALLOPROTEINASES;

EID: 16544382509     PISSN: 00652423     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-2423(04)38002-9     Document Type: Article

References (185)

1. K. Akiyama K. Shikata H. Sugimoto Changes in serum concentrations of matrix metalloproteinases, tissue inhibitors of metalloproteinases and type IV collagen in patients with various types of glomerulonephritis Res. Commun. Mol. Pathol. Pharmacol 95 1997 115 128
2. J. Albert A. Radomski A. Soop A. Sollevi C. Frostell M.W. Radomski Differential release of matrix metalloproteinase-9 and nitric oxide following infusion of endotoxin to human volunteers Acta Anaesthesiol. Scand 47 2003 407 410
3. P. Altieri C. Brunelli S. Garibaldi Metalloproteinases 2 and 9 are increased in plasma of patients with heart failure Eur. J. Clin. Invest 33 2003 648 656
4. M. Arai M. Niioka K. Maruyama Changes in serum levels of metalloproteinases and their inhibitors by treatment of chronic hepatitis C with interferon Dig. Dis. Sci 41 1996 995 1000
5. M.J. Arthur Collagenases and liver fibrosis J. Hepatol 22 1995 43 48
6. C.J. Bailey R.M. Hembry A. Alexander M.H. Irving M.E. Grant C.A. Shuttleworth Distribution of the matrix metalloproteinases stromelysin, gelatinase A and B, and collagenase in Crohn's disease and normal intestines J. Clin. Path 47 1994 113 116
7. T. Baker S. Tickle H. Wasan A.J.P. Docherty Serum metalloproteinases and their inhibitors: Markers for malignant potentiation Br. J. Cancer 70 1994 506 512
8. T. Baker S. Tickle H. Wasan A. Docherty D. Isenberg J. Waxman Serum metalloproteinases and their inhibitors: Markers for malignant potential Br. J. Cancer 70 1994 506 512
9. O.Y. Barmina H.W. Walling G.J. Fiacco J.M. Freije C. Lopez-Otin J.J. Jeffrey N.C. Partridge Collagenase-3 binds to a specific receptor and requires the low density lipoprotein receptor-related protein for internalization J. Biol. Chem 274 1999 30087 30093
10. H. Birkedal-Hansen Proteolytic remodeling of extracellular matrix Curr. Opin. Cell Biol 7 1995 728 735
11. C. Biswas Y. Zhang R. DeCastro H. Guo T. Nakamura H. Kataoka K. Nabeshima The human tumor cell-derived collagenase stimulating factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily Cancer Res 55 1995 434 439
12. S. Blankenberg H.J. Rupprecht O. Poirier Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease Circulation 107 2003 1579 1585
13. K.H. Boeker C.I. Haberkorn D. Michels P. Flemming M. Manns P. Lichtinghage Diagnostic potential of circulating TIMP-1 and MMP-2 as markers of liver fibrosis in patients with chronic hepatitis C Clin. Chim. Acta 316 2002 71 81
14. W.S. Bradham Release of matrix metalloproteinases following alcohol septal ablation in hypertrophic obstructive cardiomyopathy J. Am. Coll. Cardiol 40 2002 2165 2173
15. F.M. Brennan K.A. Browne P.A. Green J.M. Jaspar R.N. Maini M. Feldmann Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-alpha (cA2) therapy Br. J. Rheumatol 36 1997 643 650
16. P.D. Brown D.E. Kleiner E.J. Unsworth W.G. Stetler-Stevenson Cellular activation of the 72 kDa type IV collagenase⧸TIMP-2 complex Kidney Int 43 1993 163 170
17. M. Castellanos R. Leira J. Serena J.M. Pumar I. Lizasoain J. Castillo A. Davalos Plasma metalloproteinase-9 concentration predicts hemorrhagic transformation in acute ischemic stroke Stroke 34 2003 40 46
18. A.I. Catrina J. Lampa S. Ernestam E. af Klint J. Bratt L. Klareskog A.K. Ulfgren Anti-tumour necrosis factor (TNF)-alpha therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis Rheumatology (Oxford) 41 2002 484 489
19. J.B. Catterall T.E. Cawston Assays of matrix metalloproteinases (MMPs) and MMP inhibitors: Bioassays and immunoassays applicable to cell culture medium, serum, and synovial fluid Methods Mol. Biol 225 2003 353 364
20. K. Cedro A. Radomski M.W. Radomski W. Ruzyllo K. Herbaczynska-Cedro Release of matrix metalloproteinase-9 during balloon angioplasty in patients with stable angina. A preliminary study Int. J. Cardiol 92 2003 177 180
21. N.T. Cheung P.T. Dawes K.V. Poulton W.E. Ollier D.J. Taylor D.L. Mattey High serum levels of pro-matrix metalloproteinase-3 are associated with greater radiographic damage and the presence of the shared epitope in patients with rheumatoid arthritis J. Rheumatol 27 2000 882 887
22. P.K. Chua M.E. Melish Q. Yu R. Yanagihara K.S. Yamamoto V.R. Nerurkar Elevated levels of matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 during the acute phase of Kawasaki disease Clin. Diagn. Lab. Immunol 10 2003 308 314
23. I.M. Clark J.J. Morrison G.A. Hackett E.K. Powell T.E. Cawston S.K. Smith Tissue inhibitor of metalloproteinases: Serum levels during pregnancy and labor Obstet. Gynecol 83 1994 532 537
24. J.P.M. Cleutjens E.E.J.M. Creeners Integration of concepts: Cardiac extracellular matrix remodeling after myocardial infarction J. Card. Fail 8 2002 S344 348
25. A. Creange T. Sharshar T. Planchenault Matrix metalloproteinase-9 is increased and correlates with severity in Guillain-Barre syndrome Neurology 53 1999 1683 1691
26. G. Cunnane O. Fitzgerald C. Beeton T.E. Cawston B. Bresnihan Early joint erosions and serum levels of matrix metalloproteinase 1, matrix metalloproteinase 3, and tissue inhibitor of metalloproteinases 1 in rheumatoid arthritis Arthritis Rheum 44 2001 2263 2274
27. B. Davies D.W. Miles L.C. Haperfield Activity of type IV collagenases in benign and malignant breast disease Br. J. Cancer 67 1993 1126 1131
28. C.M. Dollery J.R. McEwan A.M. Henney Matrix metalloproteinases and cardiovascular disease Circ. Res 77 1995 863 868
29. R. Dorent J.L. Beaudeux S. Tezenas Circulating levels of matrix metalloproteinases in heart transplant recipients Transplant Proc 32 2000 2750 2751
30. B. Dubois S. Starckx A. Pagenstecher J. Oord B. Arnold G. Opdenakker Gelatinase B deficiency protects against endotoxin shock Eur. J. Immunol 32 2002 2163 2171
31. G.C. Durkan J.E. Nutt P.H. Rajjayabun D.E. Neal J. Lunec J.K. Mellon Prognostic significance of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in voided urine samples from patients with transitional cell carcinoma of the bladder Clin. Cancer Res 7 2001 3450 3456
32. M. Ebata Y. Fukuda I. Nakano Y. Katano N. Fujimoto T. Hayakawa Serum levels of tissue inhibitor of metalloproteinases-2 and of precursor form of matrix metalloproteinase-2 in patients with liver disease Liver 17 1997 293 299
33. I. Ebihara T. Nakamura N. Shimada H. Koide Increased plasma metalloproteinase-9 concentrations precede development of microalbuminuria in non-insulin-dependent diabetes mellitus Am. J. Kidney Dis 32 1998 544 550
34. M. Egeblad Z. Werb New functions for the matrix metalloproteinases in cancer progression Nature Rev. Cancer 2 2002 163 176
35. K. Endo Y. Maehara H. Baba Elevated levels of serum and plasma metalloproteinases in patients with gastric cancer Anticancer Res 17 1997 2253 2258
36. A. Faber-Elmann Z. Sthoeger A. Tcherniack M. Dayan E. Mozes Activity of matrix metalloproteinase-9 is elevated in sera of patients with systemic lupus erythematosus Clin. Exp. Immunol 127 2002 393 398
37. E. Farias S. Ranuncolo C. Cresta Plasma metalloproteinase activity is enhanced in the euglobulin fraction of breast and lung cancer patients Int. J. Cancer 89 2000 389 394
38. M.E. Fini J.R. Cook R. Mohan C.E. Brinkerhoff Regulation of matrix metalloproteinase gene expression W.C. Parks R.P. Meeham “Matrix Metalloproteinases” 1998 Academic Press San Diego, CA 299 356
39. R. Flisiak P. Maxwell D. Prokopowicz P.M. Timms A. Panasiuk Plasma tissue inhibitor of metalloproteinases-1 and transforming growth factor beta 1—Possible noninvasive biomarkers of hepatic fibrosis in patients with chronic B and C hepatitis Hepatogastroenterology 49 2002 1369 1372
40. H.D. Foda S. George E. Rollo Regulation of gelatinases in human airway smooth muscle cells: Mechanism of progelatinase A activation Am. J. Physiol 227 1999 L174 182
41. H.D. Foda E.E. Rollo M. Drews C. Conner K. Appelt D.R. Shalinsky S. Zucker J.D. Foda E.E. Rollo M. Drews Ventilator-induced lung injury upregulates and activates gelatinases and EMMPRIN: Attenuation by the synthetic matrix metalloproteinase inhibitor, Prinomastat Am. J. Respir. Cell Mol. Biol 25 2001 717 724
42. N. Fujimoto N. Mouri K. Iwata E. Ohuchi Y. Okada T. Hayakawa A one-step sandwich enzyme immunoassay for human matrix metalloproteinase 2 (72-kDa gelatinase⧸type IV collagenase) using monoclonal antibodies Clin. Chim. Acta 221 1993 91 103
43. Y. Galboiz S. Shapiro N. Lahat H. Rawashdeh A. Miller Matrix metalloproteinases and their tissue inhibitors as markers of disease subtype and response to interferon-beta therapy in relapsing and secondary-progressive multiple sclerosis patients Ann. Neurol 50 2001 443 451
44. Z.S. Galis J.J. Khatri Matrix metalloproteinases in vascular remodeling and atherogenesis: The good, the bad, and the ugly Circ. Res 90 2002 251 262
45. Z.S. Galis G.K. Sukhova M.W. Lark P. Libby Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques J. Clin. Invest 94 1994 2493 2503
46. H.F. Galley G.D. Macaulay N.R. Webster Matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1 and tumour necrosis factor alpha release during cardiopulmonary bypass Anaesthesia 57 2002 659 662
47. S. Garbisa G. Scagliotti L. Masiero Correlation of serum metalloproteinase levels with lung cancer metastasis and response to therapy Cancer Res 52 1992 4548 4549
48. M. Gattorno S. Vignola F. Falcini Serum and synovial fluid concentrations of matrix metalloproteinases 3 and its tissue inhibitor 1 in juvenile idiopathic arthritides J. Rheumatol 29 2002 826 831
49. D.K. George G.A. Ramm L.W. Powell L.M. Fletcher N.I. Walker L.L. Cowley D.H. Crawford Evidence for altered hepatic matrix degradation in genetic hemochromatosis Gut 42 1998 715 720
50. K. Gohji N. Fujimoto A. Fujii T. Komiyama J. Okawa M. Nakajima Prognostic significance of circulating matrix metalloproteinase-2 to tissue inhibitor of metalloproteinases-2 ratio in recurrence of urothelial cancer after complete resection Cancer Res 56 1996 3196 3198
51. K. Gohji N. Fujimoto I. Hara Serum matrix metalloproteinase-2 and its density in men with prostate cancer as a new predictor of disease extension Int. J. Cancer 79 1998 96 101
52. L.M. Golub R.T. Evans T.F. McNamara H.M. Lee N.S. Ramamurthy A non-antimicrobial tetracycline inhibits gingival matrix metalloproteinases and bone resorption Ann. New York Acad. Sci 732 1994 96 111
53. L.M. Granstrom G.E. Ekman A. Malstrom U. Ulmstem F. Woessner Serum collagenase levels in relation to the state of the human cervix during pregnancy and labor Am. J. Obstet. Gynecol 167 1992 1284 1288
54. J. Gross C.M. Lapiere Collagenolytic activity in amphibian tissues: A tissue culture assay Proc. Natl. Acad. Sci. USA 48 1962 1014 1022
55. R. Hanemaaijer H. Visser Y.T. Konttinen P. Koolwijk J.H. Verheijen A novel and simple immunocapture assay for determination of gelatinase-B (MMP-9) activities in biological fluids: Saliva from patients with Sjogren's syndrome contain increased latent and active gelatinase-B levels Matrix Biol 17 1998 657 665
56. N. Haseneen G. Vaday S. Zucker H.D. Foda Mechanical stretch induces MMP-2 release and activation in lung endothelium: Role of EMMPRIN Am. J. Physio. Lung Cell Mol. Physiol 165 2003 L541 L547
57. A. Hayasaka N. Suzuki N. Fujimoto S. Iwama E. Fukuyama Y. Kanda H. Saisho Elevated plasma levels of matrix metalloproteinase-9 (92-kd type IV collagenase⧸gelatinase B) in hepatocellular carcinoma Hepatology 24 1996 1058 1062
58. S. Hirohata S. Kusachi M. Murakami Time dependent alterations of serum matrix metalloproteinase-1 and metalloproteinase-1 tissue inhibitor after successful reperfusion of acute myocardial infarction Heart 78 1997 278 284
59. Y. Hojo U. Ikeda T. Katsuki O. Mizuno H. Fujikawa K. Shimada Matrix metalloproteinase expression in the coronary circulation induced by coronary angioplasty Atherosclerosis 161 2002 185 192
60. K. Holmbeck P. Bianco J. Caterina MT1-MMP deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover Cell 99 1999 81 92
61. M.N. Holten-Andersen G. Murphy H.J. Nielsen Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer Br. J. Cancer 80 1999 495 503
62. Y. Inokubo H. Hanada H. Ishizaka T. Fukushi T. Kamada K. Okumura Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome Am. Heart J 141 2001 211 217
63. H. Ishida N. Murata M. Tada Determining the levels of matrix metalloproteinase-9 in portal and peripheral blood is useful for predicting liver metastasis of colorectal cancer Jpn. J. Clin. Oncol 33 2003 186 191
64. S. Johansson B. Smedsrod Identification of a plasma gelatinase in preparations of fibronectin J. Biol. Chem 261 1986 4363 4366
65. K. Jung C. Laube M. Lein Matrix metalloproteinase-2 in blood does not indicate the progression of prostate cancer Int. J. Cancer 78 1998 392 393
66. K. Jung M. Lein C. Laube R. Lichtinghagen Blood specimen collection methods influence the concentration and the diagnostic validity of matrix metalloproteinase 9 in blood Clin. Chim. Acta 314 2001 241 244
67. K. Jung M. Lein N. Ulbrich B. Rudolph W. Henke D. Schnorr S.A. Loening Quantification of matrix metalloproteinases and tissue inhibitors of metalloproteinase in prostate tissue: Analytic aspects The Prostate 34 1998 130 136
68. K. Jung L. Nowak M. Lein F. Priem D. Schnorr S.A. Loening Matrix metalloproteinases 1 and 3, tissue inhibitor of metalloproteinase-1 and the complex of metalloproteinase-1⧸tissue inhibitor in plasma of patients with prostate cancer Int. J. Cancer 74 1997 220 223
69. H. Kai H. Ikeda H. Yasukawa Peripheral blood levels of matrix metalloprotease-2 and -9 are elevated in patients with acute coronary syndromes J. Am. Coll. Cardiol 32 1998 368 372
70. A. Kasahara N. Hayashi K. Mochizuki Circulating matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as serum markers of fibrosis in patients with chronic hepatitis C. Relationship to interferon response J. Hepatol 26 1997 574 583
71. N. Katoh S. Hirano M. Suehiro K. Ikenaga H. Yasuno Increased levels of serum tissue inhibitor of metalloproteinase-1 but not metalloproteinase-3 in atopic dermatitis Clin. Exp. Immunol 127 2002 283 288
72. G. Keyszer I. Lambiri R. Nagel Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1⧸TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers J. Rheumatol 26 1999 251 258
73. P.A. Klimiuk S. Sierakowski R. Latosiewicz B. Cylwik J. Skowronski Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases—Different histological variants of rheumatoid synovitis Rheumatology 41 2002 78 87
74. H. Kobayashi Z.X. Li A. Yamataka G.J. Lane T. Miyano Clinical evaluation of serum levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases as predictors of progressive fibrosis in postoperative biliary atresia patients J. Pediatr. Surg 37 2002 1030 1033
75. M. Kolben A. Lopens Jea. Blaser Proteases and their inhibitors are indicative of gestational age Eur. J. Obstet. Gynecol 68 1996 59 65
76. J. Komorowski Z. Pasieka J. Jankiewicz-Wika H. Stepien Matrix metalloproteinases, tissue inhibitors of matrix metalloproteinases and angiogenic cytokines in peripheral blood of patients with thyroid cancer Thyroid 12 2002 655 662
77. L. Kotajima S. Aotsuka M. Fujimani M. Okawa-Takatsuji M. Kinoshita M. Sumiya K. Obata Increased levels of matrix metalloproteinase-3 in sera from patients with active lupus nephritis Clin. Exp. Rheumatol 16 1998 409 415
78. M. Koulentaki V. Valatas K. Xidakis A. Kouroumalis E. Petinaki E. Castanas E. Kouroumalis Matrix metalloproteinases and their inhibitors in acute viral hepatitis J. Viral Hepat 9 2002 189 193
79. C. Laviades N. Varo J. Fernandez G. Mayor M.J. Gil I. Monreal J. Diez Abnormalities of the extracellular degradation of collagen type I in essential hypertension Circulation 98 1998 535 540
80. M.A. Lee J. Palace G. Stabler J. Ford A. Gearing K. Miller Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis. A longitudinal clinical and MRI study Brain 122 Pt. 2 1999 191 197
81. M. Lein K. Jung C. Laube Matrix-metalloproteinases and their inhibitors in plasma and tumor tissue of patients with renal cell carcinoma Int. J. Cancer 85 2000 801 804
82. N.C. Levitt F.A. Eskens K.J. O'Byrne Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer Clin. Cancer Res 7 2001 1912 1922
83. C.S. Lieber Alcohol and the liver: 1994 update Gastroenterology 106 1994 1085 1105
84. J.S. Lindholt S. Vammen H. Fasting E.W. Henneberg L. Heickendorff The plasma level of matrix metalloproteinase 9 may predict the natural history of small abdominal aortic aneurysms. A preliminary study Eur. J. Vasc. Endovasc. Surg 20 2000 281 285
85. Z. Liu J.M. Shipley X. Zhou L.A. Diaz Z. Werb R.M. Senior Gelatinase B-deficient mice are resistant to experimental bullous pemphigoid J. Exp. Med 188 1998 475 482
86. T. Lizasa Elevated levels of circulating plasma matrix metalloproteinase 9 in non-small cell lung cancer patients Clin. Cancer. Res 5 1999 149 153
87. L.S. Lohmander L. Dahlberg D. Eyre M. Lark E.J. Thonar L. Ryd Longitudinal and cross-sectional variability in markers of joint metabolism in patients with knee pain and articular cartilage abnormalities Osteoarthritis Cartilage 6 1998 351 361
88. S. Lorenzl D.S. Albers N. Relkin Increased plasma levels of matrix metalloproteinase-9 in patients with Alzheimer's disease Neurochem. Int 43 2003 191 196
89. X. Lu M. Levy I.B. Weinstein R.M. Santella Immunologic quantification of levels of Tissue Inhibitor of Metalloproteinase-1 in human colon cancer Cancer Res 51 1991 6231 6235
90. R. Magid T.J. Murphy Z.S. Galis Expression of matrix metalloproteinase-9 in endothelial cells is differentially regulated by shear stress. Role of c-Myc J. Biol. Chem 278 2003 32994 32999
91. L. Manenti P.A. Paganetti I. Floriani Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma Eur. J. Cancer 39 2003 1948 1956
92. D.H. Manicourt N. Fujimoto K. Obata E.J. Thonar Serum levels of collagenase, stromelysin-1, and TIMP-1. Age- and sex-related differences in normal subjects and relationship to the extent of joint involvement and serum levels of antigenic keratan sulfate in patients with osteoarthritis Arthritis Rheum 37 1994 1774 1783
93. D.H. Manicourt N. Fujimoto K. Obata E.J. Thonar Levels of circulating collagenase, stromelysin-1, and tissue inhibitor of matrix metalloproteinases 1 in patients with rheumatoid arthritis. Relationship to serum levels of antigenic keratan sulfate and systemic parameters of inflammation Arthritis Rheum 38 1995 1031 1039
94. F. Mannello Effects of blood collection methods on gelatin zymography of matrix metalloproteinases Clin. Chem 49 2003 339 340
95. I.M. Margulies Urinary type IV collagenase: Elevated levels are associated with bladder transitional cell carcinoma Cancer Epidemiology, Biomarkers, & Prevention 1 1992 467 474
96. F. Marin V. Roldan V. Climent A. Garcia P. Marco G.Y. Lip Is thrombogenesis in atrial fibrillation related to matrix metalloproteinase-1 and its inhibitor, TIMP-1? Stroke 34 2003 1181 1186
97. K. Masuhara T. Nakai K. Yamaguchi S. Yamasaki Y. Sasaguri Significant increases in serum and plasma concentrations of matrix metalloproteinases 3 and 9 in patients with rapidly destructive osteoarthritis of the hip Arthritis Rheum 46 2002 2625 2631
98. A. Matsuyama N. Sakai M. Ishigami Matrix metalloproteinases as novel disease markers in Takayasu arteritis Circulation 108 2003 1469 1473
99. W.D. McMillan W.H. Pearce Increased plasma levels of metalloproteinase-9 are associated with abdominal aortic aneurysms J. Vasc. Surg 29 1999 122 129
100. J.B. Meric Relevance of MMP plasma levels in malignant metastatic melanoma Proc. Am. Soc. Clin. Onc 22 2003 721
101. C.E. Metz Basic principles of ROC analysis Semin. Nucl. Med 8 1978 283 298
102. F. Monier S. Mollier M. Guillot J.J. Rambeaud F. Morel P. Zaoui Urinary release of 72 and 92 kDa gelatinases, TIMPs N-GAL and conventional prognostic factors in urothelial carcinomas Eur. Urol 42 2002 356 363
103. F. Monier A. Surla M. Guillot F. Morel Gelatinase isoforms in urine from bladder cancer patients Clin. Chim. Acta 299 2000 11 23
104. J. Montaner C.A. Molina J. Monasterio Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke Circulation 107 2003 598 603
105. M.A. Moses D. Wiederschain K.R. Loughlin D. Zurakowski C.C. Lamb M.R. Freeman Increased incidence of matrix metalloproteinases in urine of cancer patients Cancer Res 58 1998 1395 1399
106. D. Moutsiakis P. Mancuso H. Krutzsch W. Stetler-Stevenson S. Zucker Characterization of metalloproteinases and tissue inhibitors of metalloproteinases in human plasma Connective Tissue Res 28 1992 213 230
107. Y. Murawaki Y. Ikuta Y. Idobe H. Kawasaki Serum matrix metalloproteinase-1 in patients with chronic viral hepatitis J. Gastroenterol. Hepatol 14 1999 138 145
108. Y. Murawaki S. Yamada Y. Ikuta H. Kawasaki Clinical usefulness of serum matrix metalloproteinase-2 concentration in patients with chronic viral liver disease J. Hepatol 30 1999 1090 1098
109. A. Myers R. Lakey T.E. Cawston L.J. Kay K.J. Walker Serum MMP-1 and TIMP-1 levels are increased in patients with psoriatic arthritis and their siblings Rheumatology (Oxford) 2003 October 1 (Epub ahead of print)
110. H. Nagase M. Kashiwagi Aggrecanases and cartilage matrix degradation Arthritis Res. Ther 5 2003 94 103
111. H. Nagase F. Woessner Matrix metalloproteinases J. Biol. Chem 274 1999 21491 21494
112. H. Nakae S. Endo Y. Inoue Y. Fujino G. Wakabayashi K. Inada S. Sato Matrix metalloproteinase-1 and cytokines in patients with acute pancreatitis Pancreas 26 2003 134 138
113. T. Nakamura I. Ebihara N. Shimada H. Koide Effect of cigarette smoking on plasma metalloproteinase-9 concentration Clin. Chim. Acta 276 1998 173 177
114. T. Nakamura I. Ebihara N. Shimada H. Shoji H. Koide Modulation of plasma metalloproteinase-9 concentrations and peripheral blood monocyte mRNA levels in patients with septic shock: Effect of fiber-immobilized polymyxin B treatment Am. J. Med. Sci 316 1998 355 360
115. T. Nakamura C. Ushiyama S. Suzuki I. Ebihara N. Shimada H. Koide Elevation of serum levels of metalloproteinase-1, tissue inhibitor of metalloproteinase-1 and type IV collagen, and plasma levels of metalloproteinase-9 in polycystic kidney disease Am. J. Nephrol 20 2000 32 36
116. B.S. Nielsen S. Timshel L. Kjeldsen M. Sehested C. Pyke N. Borregaard K. Dano 92 kDa type IV collagenase (MMP-9) is expressed in neutrophils and macrophages but not in malignant epithelilal cells in human colon cancer Int. J. Cancer 365 1996 57 62
117. Y. Noji K. Kajinami M.A. Kawashiri Circulating matrix metalloproteinases and their inhibitors in premature coronary atherosclerosis Clin. Chem. Lab. Med 39 2001 380 384
118. Y. Noji M. Shimizu H. Ino Increased matrix metalloproteinase-2 in patients with hypertrophic cardiomyopathy with systolic dysfunction Circulation 106 2002 II, 430
119. K. Obata K. Iwata Y. Okada A one-step sandwich enzyme immunoassay for human matrix metalloproteinase 3 (stromelysin-1) using monoclonal antibodies Clin. Chim. Acta 211 1992 59 72
120. A. Oberg M. Hoyhtya B. Tavelin R. Stenling G. Lindmark Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer Anticancer Res 20 2000 1085 1091
121. Y. Ogata J.J. Enghild H. Nagase Matrix metalloproteinase 3 (stromelysin) activates the precursor for the matrix metalloproteinase 9 J. Biol. Chem 267 1992 3581 3584
122. Y. Okada H. Nagase E.D. Harris Jr. A metalloproteinase from human rheumatoid synovial fibroblasts that digests connective tissue matrix components. Purification and characterization J. Biol. Chem 261 1986 14245 14255
123. K. Omura M. Takahashi T. Omura Changes in the concentration of plasma matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases-1 (TIMP-1) after total joint replacement in patients with arthritis Clin. Rheumatol 21 2002 488 492
124. R.G. Osmers B.C. Adelmann-Grill W. Rath H.W. Stuhlsatz H. Tschesche W. Kuhn Biochemical events in cervical ripening dilatation during pregnancy and parturition Obstet. Gynecol 21 1995 185 194
125. C.M. Overall Matrix metalloproteinase substrate binding domains, modules, and exosites I.M. Clark “Matrix Metalloproteinase Protocols” 2001 Humana Press Totowa, NJ 79 120
126. M. Pavlaki S. Zucker Matrix metalloproteinase inhibitors (MMPIs): The beginning of phase I or the termination of phase III clinical trials Cancer Metastasis Reviews 22 2003 177 203
127. P. Pellegrini Simultaneous measurement of soluble carcimoembryonic antigen and the tissue inhibitor of metalloproteinase TIMP1 serum levels for use as markers of pre-invasive to invasive colorectal cancer Cancer Immunol. Immunother 49 2000 388 394
128. N. Peress E. Perillo S. Zucker Localization of tissue inhibitor of matrix metalloproteinases in Alzheimer's disease and normal brain J. Neuropath. Exper. Neurol 54 1995 16 22
129. M.D. Posthumus P.C. Limburg J. Westra H.A. Cats R.E. Stewart M.A. van Leeuwen M.H. van Rijswijk Serum levels of matrix metalloproteinase-3 in relation to the development of radiological damage in patients with early rheumatoid arthritis Rheumatology (Oxford) 38 1999 1081 1087
130. M.D. Posthumus P.C. Limburg J. Westra M.A. van Leeuwen M.H. van Rijswijk Serum matrix metalloproteinase 3 in early rheumatoid arthritis is correlated with disease activity and radiological progression J. Rheumatol 27 2000 2761 2768
131. M. Rajabi D.D. Dean J.F. Woessner High levels of serum collagenase in premature labor: A potential biochemical marker Obstet. Gynecol 69 1987 6166 6170
132. S.M. Ranuncolo Circulating 92-kilodalton matrix metalloproteinase (MMP-9) activity is enhanced in the euglobulin plasma fraction of head and neck squamous cell carcinoma Cancer 94 2002 1483 1491
133. E. Rodrigo M. Lopez Hoyos R. Escallada Changes in serum concentrations of matrix metalloproteinases in kidney transplantation Transplant Proc 32 2000 517 518
134. G.A. Rosenberg E.Y. Estrada J.E. Dencoff Matrix metalloproteinases and TIMPs are associated with blood–brain barrrier opening after reperfusion in rat brain Stroke 29 1998 2189 2195
135. P. Roux-Lombard K. Eberhardt T. Saxne J.M. Dayer F.A. Wollheim Cytokines, metalloproteinases, their inhibitors and cartilage oligomeric matrix protein: Relationship to radiological progression and inflammation in early rheumatoid arthritis. A prospective 5-year study Rheumatology (Oxford) 40 2001 544 551
136. U. Saarialho-Kere S.O. Kovacs A.P. Pentland J.E. Olerud H.G. Welgus W.C. Parks Cell-matrix interactions modulate interstitial collagenase expression by human keratinocytes actively involved in wound healing J. Clin. Invest 92 1993 2858 2866
137. G. Sangiorgi R. D'Averio A. Mauriello Plasma levels of metalloproteinases-3 and -9 as markers of successful abdominal aortic aneurysm exclusion after endovascular graft treatment Circulation 104 2001 I288 I295
138. H. Sato T. Takino Y. Okada J. Cao A. Shinagawa E. Yamamoto M. Seiki A matrix metalloproteinase expressed on the surface of invasive tumor cells Nature 370 1994 61 65
139. B. Schwartzkopff M. Fassbach B. Pelzer M. Brehm B.E. Strauer Elevated serum markers of collagen degradation in patients with mild to moderate dilated cardiomyopathy Eur. J. Heart Fail 4 2002 439 444
140. D.W. Seo H. Li L. Guedez P.T. Wingfield T. Diaz R. Salloum B.Y. Wei W.G. Stetler-Stevenson TIMP-2 mediated inhibition of angiogenesis: An MMP-independent mechanism Cell 114 2003 171 180
141. T. Sharshar M.C. Durand J.P. Lefaucheur F. Lofaso J.C. Raphael R.K. Gherardi A. Creange MMP-9 correlates with electrophysiologic abnormalities in Guillain-Barre syndrome Neurology 59 2002 1649 1651
142. I. Sopata J. Wize A. Filipowicz-Sosnowska E. Stanislawska-Biernat B. Brzezinska S. Maslinski Neutrophil gelatinase levels in plasma and synovial fluid of patients with rheumatic diseases Rheumatol Int 15 1995 9 14
143. M.E. Stearns M. Stearns Immunohistochemical studies of activated matrix metalloproteinase-2 (MMP-2a) expression in human prostate cancer Oncol. Res 8 1996 63 67
144. M.D. Sternlicht Z. Werb How matrix metalloproteinases regulate cell behavior Annu. Rev. Cell Dev. Biol 17 2001 463 516
145. W. Stetler-Stevenson R.E. Hewitt M.L. Corcoran Matrix metalloproteinases and tumor invasion: From correlation causality to the clinic Seminars in Cancer Biol 7 1996 147 154
146. W. Stoker W. Bode Structural features of a superfamily of zinc-endopeptidases: The metzincins Curr. Opin. Str. Biol 5 1995 383 390
147. H. Susskind M.H. Hymowitz Y.H. Lau Increased plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in lung and breast cancer are altered during chest radiotherapy Int. J. Radiat. Oncol. Biol. Phys 56 2003 1161 1169
148. C. Takahashi Z. Sheng T.P. Horan Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK Proc. Natl. Acad. Sci. USA 95 1998 13221 13226
149. E. Toubi A. Kessel G. Grushko E. Sabo M. Rozenbaum I. Rosner The association of serum matrix metalloproteinases and their tissue inhibitor levels with scleroderma disease severity Clin. Exp. Rheumatol 20 2002 221 224
150. F.F. Tu R.L. Goldenberg T. Tamura M. Drews S.J. Zucker H.F. Voss Prenatal plasma matrix metalloproteinase-9 (MMP-9) levels as predictor of spontaneous preterm birth Obstet. Gynecol 92 1998 446 449
151. S. Uemura H. Matsushita W. Li Diabetes mellitus enhances vascular matrix metalloproteinase activity; role of oxidative stress Circ. Res 88 2001 1291 1298
152. T. Ueno S. Tamaki H. Sugawara S. Inuzuka T. Torimura M. Sata K. Tanikawa Significance of serum tissue inhibitor of metalloproteinases-1 in various liver diseases J. Hepatol 24 1996 177 184
153. D. Ulrich E.M. Noah D. von Heimburg N. Pallua TIMP-1, MMP-2, MMP-9, and PIIINP as serum markers for skin fibrosis in patients following severe burn trauma Plast. Reconstr. Surg 111 2003 1423 1431
154. A. Vaisanen M. Kallioinen P.J. Taskinen T. Turpeenniemi-Hujanen Prognostic value of MMP-2 immunoreactive protein (72 kD type IV collagenase) in primary skin melanoma J. Pathol 186 1998 51 58
155. P.E. Van den Steen B. Dubois I. Nelissen P.M. Rudd R.A. Dwek G. Opdenakker Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9) Crit. Rev. Biochem. Mol. Biol 37 2002 376 536
156. T. Vartio M. Baumann Human gelatinase⧸type IV collagenase is a regular plasma component FEBS Letters 155 1989 285 289
157. T.H. Vu J.M. Shipley G. Bergers MMP-9⧸gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes Cell 93 1998 411 422
158. T.H. Vu Z. Werb Matrix metalloproteinases: Effectors of development and normal physiology Genes Dev 14 2000 2123 2133
159. M.S. Vuoristo P. Kellokumpu-Lehtinen L.M. Parvinen M. Hahka-Kemppinen M. Korpela E. Kumpulainen S. Laine Serum matrix metalloproteinase-2 as a prognostic marker in advanced cutaneous melanoma Acta Oncol 39 2000 877 879
160. K.M. Walsh P. Timms S. Campbell R.N. MacSween A.J. Morris Plasma levels of matrix metalloproteinase-2 (MMP-2) and tissue inhibitors of metalloproteinases-1 and-2 (TIMP-1 and TIMP-2) as noninvasive markers of liver disease in chronic hepatitis C: Comparison using ROC analysis Dig. Dis. Sci 44 1999 624 630
161. J.C. Wang A. Novetsky C. Chen A.D. Novetsky Plasma matrix metalloproteinase and tissue inhibitor of metalloproteinase in patients with agnogenic myeloid metaplasia or idiopathic primary myelofibrosis Br. J. Haematol 119 2002 709 712
162. E.M. Wilson H.R. Gunasinghe M.L. Coker Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure J. Card. Fail 8 2002 390 398
163. M. Wood K. Fudge J.L. Mohler A.R. Frost F. Garcia M. Wang M.E. Stearns In situ hybridization studies of metalloproteinases 2 and 9 and TIMP-1 and TIMP-2 expression in human prostate cancer Clin. Exp. Metastasis 15 1997 246 258
164. J.D. Wufkuhle L. Liotta E.F. Petricoin Proteomic applications for the early detection of cancer Nature Reviews Cancer 3 2003 267 275
165. H. Yamanaka Y. Matsuda M. Tanaka W. Sendo H. Nakajima A. Taniguchi N.Y. Kamatani Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis Arthritis Rheum 43 2000 852 858
166. L. Yan N. Borregaard L. Kjeldsen M.A. Moses The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B⧸MMP-9 and neutrophil gelatinase-associated lipocalcin (NGAL) J. Biol. Chem 276 2001 37258 37265
167. Z. Yang D.K. Strickland P. Bornstein Extracellular MMP-2 levels are regulated by the low-density lipoprotein-related scavenger receptor and thrombospondin 2 J. Biol. Chem 276 2001 8403 8408
168. N. Yazawa K. Kikuchi H. Ihn M. Fujimoto M. Kubo T. Tamaki Tamaki Serum levels of tissue inhibitor of metalloproteinases 2 in patients with systemic sclerosis J. Am. Acad. Dermatol 42 2000 70 75
169. S. Ylisirnio M. Hoyhtya T. Turpeenniemi-Hujanen Serum matrix metalloproteinases-2, -9, and tissue inhibitors of metalloproteinases-1, -2 in lung cancer—TIMP-1 as a prognostic marker Anticancer Res 20 2000 1311 1316
170. Y. Yoshihara K. Obata N. Fujimoto K. Yamashita T. Hayakawa M. Shimmei Increased levels of stromelysin-1 and tissue inhibitor of metalloproteinases-1 in sera from patients with rheumatoid arthritis Arthritis Rheum 38 1995 969 975
171. T. Yoshikawa Tissue inhibitor of matrix metalloproteinase-1 in the plasma of patients with gastric carcinoma. A possible marker for serosal invasion and metastasis Cancer 86 1999 1929 1935
172. S.A. Young-Min C. Beeton R. Laughton Serum TIMP-1, TIMP-2, and MMP-1 in patients with systemic sclerosis, primary Raynaud's phenomenon, and in normal controls Ann. Rheum. Dis 60 2001 846 851
173. N. Yukawa T. Yoshikawa M. Akaike Plasma concentration of tissue inhibitor of matrix metalloproteinase 1 in patients with colorectal carcinoma Br. J. Surg 88 2001 1596 1601
174. Z.S. Zeng Y. Huang A.M. Cohen J.G. Guillem Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix metalloproteinase-9 J. Clin. Oncol 14 1996 3133 3140
175. S. Zucker J. Cao C.J. Molloy Role of matrix metalloproteinases and plasminogen activators in cancer and metastasis: Therapeutic strategies B.C Baguley D.J. Kerr “Anticancer Drug Development” 2002 Academic Press San Diego, CA 91 122
176. S. Zucker M. Hymowitiz C. Conner Measurement of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in blood and tissues Ann. New York Acad. Sci 878 1999 212 227
177. S. Zucker M. Hymowitz C. Conner Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications Ann. NY Acad. Sci 878 1999 212 227
178. S. Zucker R.M. Lysik B.I. DiMassimo Plasma assay of gelatinase B: Tissue inhibitor of metalloproteinase (TIMP) complexes in cancer Cancer 76 1995 700 708
179. S. Zucker R.M. Lysik M. Gurfinkel Immunoassay of type IV collagenase⧸gelatinase (MMP-2) in human plasma J. Immunol. Methods 148 1992 189 198
180. S. Zucker R.M. Lysik H.M. Zarrabi Plasma assay of matrix metalloproteinases (MMPs) and MMP: Inhibitor complexes in cancer Ann. New York Acad. Sci 732 1994 248 262
181. S. Zucker R.M. Lysik M.H. Zarrabi Type IV collagenase⧸gelatinase (MMP2) is not increased in plasma of patients with cancer Cancer Epidemiology, Biomarkers, and Prevention 1 1992 475 479
182. S. Zucker R.M. Lysik M.H. Zarrabi Elevated plasma stromelysin levels in arthritis J. Rheumatol 21 1994 2329 2333
183. S. Zucker R.M. Lysik M.H. Zarrabi U. Moll Mr 92,000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer Cancer Res 53 1993 140 146
184. S. Zucker P. Mancuso B. DiMassimo R.M. Lysik C. Conner C.-L. Wu Comparison of techniques for measurement of gelatinase⧸type IV collagenases: Enzyme-linked immunoassays versus substrate degradation assays Clin. Exper. Metastasis 12 1994 13 23
185. S. Zucker N. Mian M. Drews Increased serum stromelysin-1 in systemic lupus erythematosus: Lack of correlation with disease activity J. Rheumatol 26 1999 78 80